ADOPTS: Non-invasive Pulmonary Artery Prediction

Sponsor
Silverleaf Medical Sciences INC (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05622695
Collaborator
PIH Health Good Samaritan Hospital (Other)
25
1
10
2.5

Study Details

Study Description

Brief Summary

Cardiac remote monitoring devices have expanded our ability to track physiological changes used in the diagnosis and management of patients with cardiac disease. Implantable remote monitoring technologies have been shown to predict heart failure events, and guide therapy to reduce heart failure hospitalizations. The CardioMEMs System, the most studied and established remote monitoring system, relies on a pulmonary artery implant for continuous PAP measurement. However, there are no commercially available wearable systems that can reproduce continuous PAP tracings.

This study aims to determine if a machine-learning algorithm with data from a wearable cardiac remote-monitoring system incorporating EKG, heart sounds, and thoracic impedance can reproduce a continuous PAP tracing obtained during right heart catheterization.

Condition or Disease Intervention/Treatment Phase
  • Device: catheterization

Study Design

Study Type:
Observational
Anticipated Enrollment :
25 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Study to Determine if Novel Wearable Monitoring System and Machine-Learning Algorithm Can Model Continuous Pulmonary Artery Pressure Recordings in Human Subjects
Actual Study Start Date :
Oct 30, 2022
Anticipated Primary Completion Date :
Apr 30, 2023
Anticipated Study Completion Date :
Aug 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Catheterization Arm

Participants will be limited to adults older than 18 years of age, able to consent, planned for the cardiac catheterization lab for a right heart catheterization or in the cardiac care unit with an existing arterial line or Swan-Ganz catheter actively measuring the pulmonary artery pressure on a continuous basis.

Device: catheterization
Swan-Ganz catheterization (also called right heart catheterization or pulmonary artery catheterization) is the passing of a thin tube (catheter) into the right side of the heart and the arteries leading to the lungs. It is done to monitor the heart's function and blood flow and pressures in and around the heart.

Outcome Measures

Primary Outcome Measures

  1. The correlation of pulmonary artery pressure values measured by Sawn Gan catheter and that derived by a machine learning algorithm [the Swan-Ganz catheter obtains the pulmonary artery pressures for a minimum of 5 minutes.]

    The primary objective of this study is to determine if a machine-learning algorithm with data from a wearable device can reproduce simultaneous pulmonary artery pressure obtained during right heart catheterization or data obtained from a Sawn Ganz catheter already in place in the setting of cardiac care unit admission.

  2. The correlation of pulmonary artery wedge pressure values measured by Sawn Gan catheter and that derived by a machine learning algorithm [the Swan-Ganz catheter obtains wedge pressures first for a minimum of 20 seconds (20-30 seconds).]

    The second objective of this study is to determine if a machine-learning algorithm with data from a wearable device can reproduce simultaneous pulmonary artery wedge pressure obtained during right heart catheterization or data obtained from a Sawn Ganz catheter already in place in the setting of cardiac care unit admission.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Subjects age 18+ years

  2. Undergoing a right heart cardiac catheterization or in the cardiac care unit with active monitoring using an arterial line or Swan-Ganz catheter.

Exclusion Criteria:
  1. Vulnerable population

  2. Unable to consent for any reason

  3. Unstable patient

  4. Known skin reaction to latex or adhesives

Contacts and Locations

Locations

Site City State Country Postal Code
1 PIH Good Samaritan Hospital Los Angeles California United States 90017

Sponsors and Collaborators

  • Silverleaf Medical Sciences INC
  • PIH Health Good Samaritan Hospital

Investigators

  • Study Chair: Jianwei Zheng, Ph.D., Silverleaf Medical Sciences
  • Principal Investigator: Ihab Alomari, Dr., PIH Good Samaritan Hospital
  • Study Director: Islam Abudayyeh, Dr., Loma Linda University Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Silverleaf Medical Sciences INC
ClinicalTrials.gov Identifier:
NCT05622695
Other Study ID Numbers:
  • ADOPTS_GOODSAM
First Posted:
Nov 21, 2022
Last Update Posted:
Nov 21, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 21, 2022